{"id":"dexametasone-medium","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes (agitation, depression)"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone enters cells and binds to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of inflammatory responses. It is commonly used to manage inflammation, autoimmune conditions, and as an adjunctive therapy in various acute and chronic diseases.","oneSentence":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:11.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders"},{"name":"Cerebral edema"},{"name":"Acute respiratory distress syndrome (ARDS)"},{"name":"Severe COVID-19"}]},"trialDetails":[{"nctId":"NCT07052201","phase":"PHASE3","title":"Dexamethasone Regimens for BPD Prevention in Preterm Infants","status":"NOT_YET_RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2026-02-01","conditions":"Infant, Premature, Bronchopulmonary Dysplasia (BPD)","enrollment":970}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3635,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dexametasone. Medium","genericName":"Dexametasone. Medium","companyName":"The Children's Hospital of Zhejiang University School of Medicine","companyId":"the-children-s-hospital-of-zhejiang-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm. Used for Inflammatory and autoimmune disorders, Cerebral edema, Acute respiratory distress syndrome (ARDS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}